Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

AIM ImmunoTech Inc AIM

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.


NYSEAM:AIM - Post by User

Bullboard Posts
Post by Sinbobon Jan 17, 2013 2:41pm
403 Views
Post# 20852537

Other considerations

Other considerations

It is not uncommon that a concerted effort by a core group via a hedge fund, broker, market maker or other, has and is being made to drive the stock down as far as possible in order to make $. Shorting ( illegally or otherwise) from the highs all the way down could reap millions if/when the stock reverses. The more the stock falls on fear and fear mongering, the more $ for the shorters. If HEB is approved by the FDA for conitnuning trials in Feb. or later...it will move back up and the shorts who  borrowed the shares high and sold, will trade the lower valued shares in for the higher pirced one down the road. The ultimate losers are the honest shareholders who panicked and sold... and had their hopes for a class action law suit pay day dashed to smitherines.

This will be an intersting stock to watch as time goes on.Ask yourself one question, who has more credibility at this time... the scammer, the lawyers of the managment at HEB? Why not call the co. for some information?... or the FDA?

Bullboard Posts